A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection (AMR) in ABO Blood Group Incompatible Living Donor Kidney Transplantation (ABOi LDKTx).

Trial Profile

A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection (AMR) in ABO Blood Group Incompatible Living Donor Kidney Transplantation (ABOi LDKTx).

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 23 Jul 2015

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms ABOi
  • Most Recent Events

    • 18 Jun 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov record.
    • 16 Apr 2014 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 10 Jul 2013 Planned End Date changed from 1 Sep 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top